Lessons from innovation in drug-device combination products

Area of Science:

• Medical Product Development
• Regulatory Science
• Biotechnology

Background:

• Drug-device combination products represent a significant evolution in medical technology.
• These products integrate therapeutic agents with medical devices, presenting unique development and regulatory challenges.
• Existing literature often focuses on individual components rather than the synergistic aspects of combination products.

Purpose of the Study:

• To analyze the challenges and opportunities in developing drug-device combination products.
• To provide lessons for future generations of combination products based on case studies.
• To understand the impact of regulatory pathways on market introduction and corporate strategy.

Main Methods:

• Case study analysis of drug-eluting stents and transdermal patches.
• Examination of regulatory approval dynamics for novel combination products.
• Analysis of the influence of primary function determination on market leadership and corporate structure.

Main Results:

• The primary barrier for new combination products is identifying the correct regulatory oversight center.
• The first product approval in a new class establishes the precedent and reduces uncertainty for subsequent products.
• Sponsors play a crucial role in defining the primary function, influencing regulatory pathways and market entry.

Conclusions:

• Early definition of the primary function is critical for successful drug-device combination product development.
• Regulatory clarity is essential for reducing uncertainty and facilitating market access.
• The strategic decisions made during the initial development phase shape the future landscape for combination products and associated industries.